←
JAMA Oncology18,823 posts
JAMA Oncology avatar✓

JAMA Oncology ✓

@JAMAOnc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

◷ Joined September 2014▧ 2,494 Photos and videos
JAMA Oncology avatar
JAMA Oncology@JAMAOnc·23h

Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity. ➡️ Register now: ja.ma/4t4day5

Post attachment
JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Nov 6

In ERBB2-positive metastatic #BreastCancer, first-line treatment is shifting beyond taxane-based induction toward newer regimens and expanded maintenance options that may change treatment sequencing and duration. ja.ma/3UHbgqv

JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Nov 5

Among trainees providing #CancerCare, representation of physicians from groups underrepresented in medicine increased after 2020, but still did not match the diversity of the general US population in 2025. ja.ma/4zoqO1l

JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Oct 26

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3W97574

JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Oct 25

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4B6SpW4

JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Oct 23

📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/48a7OYp

0:50
JAMA Oncology avatar
JAMA Oncology@JAMAOnc·Oct 23

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/4B5fVmv